...
机译:四肽Arg-Leu-Tyr-glu的N-末端改性,血管内皮生长因子受体-2(VEGFR-2)拮抗剂,通过增加其对血清肽酶的稳定性来改善抗肿瘤活性
Kangwon Natl Univ Dept Mol &
Cellular Biochem Chunchon Gangwon Do South Korea;
Kangwon Natl Univ Dept Mol &
Cellular Biochem Chunchon Gangwon Do South Korea;
Kangwon Natl Univ Dept Mol &
Cellular Biochem Chunchon Gangwon Do South Korea;
Kangwon Natl Univ Dept Mol &
Cellular Biochem Chunchon Gangwon Do South Korea;
Kangwon Natl Univ Dept Mol &
Cellular Biochem Chunchon Gangwon Do South Korea;
Kangwon Natl Univ Dept Mol &
Cellular Biochem Chunchon Gangwon Do South Korea;
Kangwon Natl Univ Dept Mol &
Cellular Biochem Chunchon Gangwon Do South Korea;
Kangwon Natl Univ Dept Mol &
Cellular Biochem Chunchon Gangwon Do South Korea;
Kangwon Natl Univ Coll Nat Sci Dept Biochem Chunchon Gangwon Do South Korea;
Kangwon Natl Univ Dept Life Sci Coll Nat Sci Chunchon Gangwon Do South Korea;
Kangwon Natl Univ Sch Med Dept Neurobiol Chunchon Gangwon Do South Korea;
Hanyang Univ Hosp Dept Anesthesiol &
Pain Med Seoul South Korea;
Kangwon Natl Univ Dept Mol &
Cellular Biochem Chunchon Gangwon Do South Korea;
Yonsei Univ Coll Life Sci &
Biotechnol Dept Biochem Seoul South Korea;
Kangwon Natl Univ Dept Mol &
Cellular Biochem Chunchon Gangwon Do South Korea;
机译:四肽Arg-Leu-Tyr-glu的N-末端改性,血管内皮生长因子受体-2(VEGFR-2)拮抗剂,通过增加其对血清肽酶的稳定性来改善抗肿瘤活性
机译:血管内皮生长因子受体2缺陷的小鼠中血管内皮生长因子受体2的丰富度增加有助于增加血管生成
机译:血管生成分子血管内皮生长因子-A,血管内皮生长因子受体-1和血管内皮生长因子受体-2的免疫组化表达对经典霍奇金淋巴瘤患者的预后意义
机译:血管生成中血管内皮生长因子受体2(VEGFR-2)的翻译后修饰
机译:慢性脑积水实验模型中血管内皮生长因子受体2(VEGFR-2)和血管密度的变化。
机译:N4-苯基储存-6-(24-二氯苯基甲基)-7H-吡咯的合成和生物活性23-D嘧啶-24-二胺作为血管内皮生长因子受体-2抑制剂和抗血管生成和抗肿瘤代理人
机译:四肽氨基氨基菌Tyr-glu,血管内皮生长因子受体-2(VEGFR-2)拮抗剂,通过提高血清肽酶的稳定性来改善抗肿瘤活性